Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: Association with B-cell markers

Molecular Diagnosis and Therapy

Volumn 14, Issue 1, 2010, Pages 43-48

  Pyrpasopoulou, Athina ^a   Douma, Stella ^a   Triantafyllou, Areti ^a   Simoulidou, Elisavet ^a   Samara, Magda ^a   Parapanisiou, Efthymia ^a   Aslanidis, Spyros ^a  

^a Aristotle University of Thessaloniki   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD20 ANTIGEN RECEPTOR; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; RHEUMATOID FACTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 76949095678     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256352     Document Type: Article

References (21)

1. Kwan-Morley J, Albert D. B-cell inhibitors as therapy for rheumatoid arthritis: an update. Curr Rheumatol Rep 2007; 9: 401-406
2. Looney RJ. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs 2006; 66: 625-639
3. Cohen SB, Emery P, GreenwaldMW, et al., REFLEX TrialGroup.Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-2806
4. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al., DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-1400
5. Szodoray P, Alex P, Dandapani V, et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 2004; 60: 209-218
6. Roll P, Dörner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566-1575
7. Dass S, Rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2993-2999
8. Breedveld F, Agarwal S, YinM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47: 1119-1128
9. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20: 444-449
10. Thurlings RM, Vos K, Gerlag DM, et al. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of retreatment in initial nonresponders versus initial responders. Arthritis Rheum 2008; 58: 3657-3664
11. Smolen JS, Aletaha D, Grisar J, et al. The need for prognosticators in rheumatoid arthritis: biological and clinical markers. Where are we now? Arthritis Res Ther 2008; 10: 208
12. Palanichamy A, Roll P, Theiss R, et al. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. Arthritis Rheum 2008; 58: 3665-3674
13. Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 2009; 145: 173-179
14. Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (the ARISE trial): I. Clinical and synovial biomarker results. Ann Rheum Dis 2008; 67: 402-408
15. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 772-778
16. Frampton JE, Scott LJ. Rituximab: in rheumatoid arthritis. Biodrugs 2007; 21: 333-341
17. Bokarewa M, Lindholm C, Zendjanchi K, et al. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol 2007; 66: 476-483
18. Erwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-211
19. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-2154
20. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly lowdose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukaemia. J Immunol 2006; 177: 7435-7443
21. Silverman GJ, Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 2008; 223: 175-185